Atrix Leuprogel NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Atrix NDA for Leuprogel Three-Month Depot (22.5 mg leuprolide acetate) is submitted Sept. 26. Atrix submitted an NDA in March for a one-month depot formulation and has a four-month version of the prostate cancer therapy in Phase III trials. Sanofi-Synthelabo will market the products in North America